NCT03674866已完成不适用
A Canadian Multi-centre, Retrospective, Non-interventional Study of the Effectiveness of Tresiba® (Insulin Degludec) After Switching Basal Insulin in a Population With Type 1 or Type 2 Diabetes Mellitus CAN-TREAT (CANadian TREsiba AudiT)
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 662
- 试验地点
- 1
- 主要终点
- Change in Glycated Haemoglobin (HbA1c)
研究概览
简要总结
The purpose of this study is to collect historical data in real life conditions in a large group of people who have type 1 or type 2 diabetes and were treated with Tresiba® (insulin degludec) for at least 6 months. Data will be collected beginning 6 months before the participant started Tresiba® up to around 6 months after the participant started taking insulin degludec.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Informed consent will be obtained before any study-related activities. Study-related activities are any data collection from the medical records of the patient
- •Male or female age greater than or equal to 18 years at the time of insulin degludec initiation
- •Type 1 diabetes mellitus or insulin-treated type 2 diabetes mellitus patients
- •Switched to insulin degludec (± prandial insulin) after any basal insulin (± prandial insulin). Switch must have occurred at least 6 months prior to data collection and the patient may or may not be treated with insulin degludec at the time of patient selection
- •Previously treated with any basal insulin (± prandial insulin) for at least 6 months prior to switching to insulin degludec
- •At least one documented medical visit in the first 6 months (closest value in 3 to 9 months window) after insulin degludec initiation
- •Minimum available data at the time of insulin degludec initiation: age, type of diabetes, HbA1c, duration of diabetes, duration and type of insulin treatment, medical follow-up at the study site for at least 1 year, and an estimated glomerular filtration rate (eGFR) value in the last 12 ±6 months (full data period)
排除标准
- •Previous participation in this study. Participation is defined as having signed the Informed Consent in this study
- •Patients treated by continuous subcutaneous insulin infusion or premix insulin in the 6 months prior to receiving Tresiba
研究组 & 干预措施
Patients with diabetes
Patients with type 1 diabetes and type 2 diabetes who received at least one prescription of insulin degludec (Tresiba®).
干预措施: Insulin degludec (Drug)
结局指标
主要结局
Change in Glycated Haemoglobin (HbA1c)
时间窗: Baseline (up to 3 months prior to switch), 6 months after switch to insulin degludec
measured in % point
次要结局
- Change in percentage of patients with HbA1c below 7%(Baseline (up to 3 months prior to switch), 6 months after switch to insulin degludec)
- Change in percentage of patients with HbA1c below 7.5%(Baseline (up to 3 months prior to switch), 6 months after switch to insulin degludec)
- Change in percentage of patients with HbA1c below 8.0%(Baseline (up to 3 months prior to switch), 6 months after switch to insulin degludec)
- Change in the mean Fasting Plasma Glucose (FPG)(Baseline (up to 3 months prior to switch), 6 months after switch to insulin degludec)
- Insulin degludec dose(6 months after switch to insulin degludec)
- Change in the percentage of patients with at least one hypoglycaemic episode (overall, nonsevere,non-severe)(After change to insulin degludec (0 to 6 months))
- Change in the rates of hypoglycaemic episodes (overall, non-severe, severe, nocturnal)(After change to insulin degludec (0 to 6 months))
- Percentage of patients continuing insulin degludec(After change to insulin degludec (0 to 6 months))
- Reason(s) for starting insulin degludec(At time of switch to insulin degludec (week 0))
- Reason(s) for discontinuing insulin degludec(At time of discontinuing insulin degludec (0 to 6 months))
- Change in the mean daily insulin doses (total, basal, prandial)(Baseline (up to 3 months prior to switch), 6 months after switch to insulin degludec)
- Change in the number of concomitant non-insulin glucose-lowering drug classes(Baseline (up to 3 months prior to switch), 6 months after switch to insulin degludec)
- Change in body weight(Baseline (up to 3 months prior to switch), 6 months after switch to insulin degludec)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Observational Study on the Use of Akynzeo® in Patients Receiving HECChemotherapy-Induced Nausea and VomitingNCT03649230Purdue Pharma, Canada207
进行中（未招募）
不适用
Non-interventional Study on Osilodrostat in Patients With Endogenous Cushing's SyndromeEndogenous Cushing's SyndromeNCT05382156RECORDATI GROUP206
进行中（未招募）
不适用
Evaluation of Dyslipidemia Management After Statin and Ezetimibe Complex TreatmentDyslipidemiasNCT05614765Daewoong Pharmaceutical Co. LTD.18,000
已完成
不适用
A Real-world Study to Assess Safety and Effectiveness of Secukinumab in Pediatric Plaque Psoriasis Patients in ChinaModerate to Severe Chronic Plaque PsoriasisNCT05388916Novartis Pharmaceuticals42
已完成
不适用
Retrospective Study in a NSCLC M+ pEGFR Mutated Non-small Cell Lung Cancer PatientsNCT01795352AstraZeneca187